|Target||TGF beta 1|
|(what is this?)|
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. It was dropped from further development in favour of fresolimumab, which was being developed by Genzyme as of 2006.
In 2004, CAT and Genzyme revealed that Phase I/II trials of metelimumab for scleroderma showed this antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.
Initial trials targeted the skin condition scleroderma but, after some unsuccessful clinical trial results, the product was dropped in favour of fresolimumab, which was being developed by Genzyme as of 2006.
- Sorbera LA (2004). "Metelimumab: Agent for scleroderma prop inn human anti-TGF-β1 monoclonal antibody". Drugs of the Future. 29 (11): 1081–3. doi:10.1358/dof.2004.029.11.860002.
- Foley S (10 February 2004). "CAT may abandon skin drug after trial results disappoint". Cite journal requires
- "Tasidotin". Genzyme. 2006. Archived from the original on 2006-09-02. Retrieved 2009-07-27.
- "Genzyme General and Cambridge Antibody Technology To Collaborate on Development of Human Anti-TGF-beta Monoclonal Antibodies". PR News Wire. Archived from the original on 15 July 2011.
- "Cambridge Antibody, Genzyme to collaborate on human anti-TGFBeta monoclonals". Drug Discovery Online. 2 October 2000.
- "CAT-192 is safe but efficacy in doubt". The Pharma Letter. 16 February 2002.
- Clinical trial number NCT00043706 for "Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis" at ClinicalTrials.gov